

**OPEN**

Author Correction: MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway

Chao Fang, Yi-Xin Chen, Na-Yiyuan Wu, Ji-Ye Yin, Xiang-Ping Li, Hsuan-Shun Huang, Wei Zhang, Hong-Hao Zhou & Zhao-Qian Liu

Correction to: *Scientific Reports* <https://doi.org/10.1038/srep40384>, published online 11 January 2017

This Article contains an error in Figure 4D, where the image for the blank condition was inadvertently duplicated for the NC panel. The correct Figure 4 and its accompanying legend appear below.

Published online: 11 November 2021




Figure 4. The A549 cell line and cells transfected with negative control (NC) and the miR-488 mimic were used in the following assays. Cell viability (a) was tested with an MTT assay, and colony formation (b) was measured with crystal violet staining. All these showed that miR-488 could inhibit the proliferation of A549 cells. Wound healing (c) and transwell assays with Matrigel (d) were tested in A549 cells with miR-488 overexpression. The percent of wounds closed or number of cells migrating through the membrane were counted and are compared in the diagrams. The cell cycle (e) was evaluated with flow cytometry. The data from three independent experiments are given as the mean \pm SD (*P < 0.05).



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021